JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease

Journal of the Neurological Sciences

Volumn 285, Issue 1-2, 2009, Pages 172-177

  Wang, Yongsheng ^a   Zhang, Yuxin ^a   Wei, Zifeng ^a   Li, Hui ^a   Zhou, Hongxia ^a   Zhang, Zhiyong ^a   Zhang, Zuofeng ^a  

^a NORTH CHINA COAL MEDICAL COLLEGE   (China)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cyclooxygenase 2; Dopaminergic neuron; JNK pathway; Mouse; Parkinson's disease; Phospho c Jun

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOOXYGENASE 2; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; CELL PROTECTION; CONTROLLED STUDY; CYTOPLASM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTHRACENES; CELL DEATH; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOPAMINE; ENZYME INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MOVEMENT DISORDERS; NEURONS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; RANDOM ALLOCATION; SUBSTANTIA NIGRA;

EID: 69549127950     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.06.034     Document Type: Article

References (36)

1. Oertel W.H., and Ellgring H. Parkinson's disease-medical education and psychosocial aspects. Patient Educ Couns 26 (1995) 71-79
2. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15 (2002) 991-998
3. Etminan M., Carleton B.C., and Samii A. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 15 (2008) 576-577
4. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp Neurol 193 (2005) 279-290
5. Marchetti B., and Abbracchio M.P. To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol Sci 26 (2005) 517-525
6. Rogers J., Mastroeni D., Leonard B., Joyce J., and Grover A. Neuroi'nflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. Int Rev Neurobiol 82 (2007) 235-246
7. Reksidler A.B., Lima M.M., Zanata S.M., Machado H.B., da Cunha C., Andreatini R., et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560 (2007) 163-175
8. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63 (2004) 901-910
9. Vijitruth R., Liu M., Choi D.Y., Nguyen X.V., Hunter R.L., and Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 3 (2006) 6
10. Wang T., Pei Z., Zhang W., Liu B., Langenbach R., Lee C., et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19 (2005) 1134-1136
11. Knott C., Stem G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenase-1 and -2. Mol Cell Neurosci 16 (2000) 724-739
12. Ip Y.T., and Davis R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammatory to development. Curr Opin Cell Biod 10 (1998) 205-219
13. Adler V., Polotskaya A., Wagner F., and Kraft A.S. Affinitypurified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J Biol Chem 267 (1992) 17001-17005
14. Hibi M., Lin A., Smeal T., Minden A., and Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7 (1993) 2135-2148
15. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an antthrapyra-zolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci 98 (2001) 13681-13686
16. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
17. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., et al. The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetra-hydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76 (2001) 1265-1274
18. Xia X.G., Harding T., Weller M., Bieneman A., Uney J.B., and Schulz J.B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A. 98 (2001) 10433-10438
19. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 22 (1999) 51-61
20. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 (1994) 1025-1037
21. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69 (2000) 145-182
22. Pasinetti G.M. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 54 (1998) 1-6
23. Chen H., Zhang S.M., Hernán M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003) 1059-1064
24. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci 100 (2003) 5473-5478
25. Waetzig V., Czeloth K., Hidding U., Mielke K., Kanzow M., Brecht S., et al. C-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 50 (2005) 235-246
26. Nieminen R., Leinonen S., Lahti A., Vuolteenaho K., Jalonen U., Kankaanranta H., et al. Inhibitors of mitogen-activated protein kinases downregulate COX-2 expression in human chondrocytes. Mediators Inflamm 2005 (2005) 249-255
27. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-252
28. Silva R.M., Kuan C.Y., Rakic P., and Burke R.E. Mixed lineage kinase-c-jun N-Terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov Disord 20 (2005) 653-664
29. Kuan C.Y., and Burke R.E. Targeting the JNK signaling pathway for Stroke and Parkinson's disease therapy. Curr Drug Targets CNS Neurol Disord 4 (2005) 63-67
30. Okada Y., Voznesensky O., Herschman H., Harrison J., and Pilbeam C. Identification of multiple cis-acting elements mediating the induction of prostaglandin G/H synthase-2 by phorbol ester in murine osteblastic cells. J Cell Biochem 78 (2000) 197-209
31. Ogasawara A., Arakawa T., Kaneda T., Takuma T., Sato T., Kaneko H., et al. Fluid shear stress-induced cyclooxygenase-2 expression is mediated by C/EBP beta, cAMP-response element-binding protein, and AP-1 in osteoblastic MC3T3-EI cells. J Biol Chem 276 (2001) 7048-7054
32. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 288 (1999) 421-427
33. Maroney A.C., Finn J.P., Connors T.J., Durkin J.T., Angeles T., Gessner G., et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 276 (2001) 25302-25308
34. Harris C.A., Deshmukh M., Tsui-Pierchala B., Maroney A.C., and Johnson Jr. E.M. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J Neurosci 22 (2002) 103-113
35. Hou D.X., Yanagita T., Uto T., Masuzaki S., and Fujii M. Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: structure activity relationship and molecular mechanisms involved. Biochem Pharmacol 70 (2005) 417-425
36. Han Z., Chang L., Yamanishi Y., Karin M., and Firestein G.S. Joint damage and inflammation in c-Jun N terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 46 (2002) 818-823